Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.

Salvatore Mangano, D'Aniello, Balestri, Parisi, Zamponi, Spalice, Fels, Veggiotti, Pascotto, Franzoni, Curatolo, Grosso, Coppola, Alberto Verrotti, Habetswallner

Risultato della ricerca: Article

39 Citazioni (Scopus)

Abstract

Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ‡50% seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6%).Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5%) and increased in five patients (13.1%). Elevenpatients (28.9%) reported adverse side effects. Vomiting was reported in five patients(13.1%); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.
Lingua originaleEnglish
pagine (da-a)246-251
Numero di pagine6
RivistaEUROPEAN JOURNAL OF NEUROLOGY
Volume18
Stato di pubblicazionePublished - 2011

Fingerprint

Brain Diseases
Seizures
Pharmaceutical Preparations
Lennox Gastaut Syndrome
rufinamide
Sleep Stages
Appetite
Migraine Disorders
Vomiting
Young Adult

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cita questo

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. / Mangano, Salvatore; D'Aniello; Balestri; Parisi; Zamponi; Spalice; Fels; Veggiotti; Pascotto; Franzoni; Curatolo; Grosso; Coppola; Verrotti, Alberto; Habetswallner.

In: EUROPEAN JOURNAL OF NEUROLOGY, Vol. 18, 2011, pag. 246-251.

Risultato della ricerca: Article

Mangano, S, D'Aniello, Balestri, Parisi, Zamponi, Spalice, Fels, Veggiotti, Pascotto, Franzoni, Curatolo, Grosso, Coppola, Verrotti, A & Habetswallner 2011, 'Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.', EUROPEAN JOURNAL OF NEUROLOGY, vol. 18, pagg. 246-251.
Mangano, Salvatore ; D'Aniello ; Balestri ; Parisi ; Zamponi ; Spalice ; Fels ; Veggiotti ; Pascotto ; Franzoni ; Curatolo ; Grosso ; Coppola ; Verrotti, Alberto ; Habetswallner. / Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. In: EUROPEAN JOURNAL OF NEUROLOGY. 2011 ; Vol. 18. pagg. 246-251.
@article{7938075991d34794bae6fa97bf90fd85,
title = "Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.",
abstract = "Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5{\%}) had a ‡50{\%} seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6{\%}).Three patients (7.9{\%}) had a 25–49{\%} seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5{\%}) and increased in five patients (13.1{\%}). Elevenpatients (28.9{\%}) reported adverse side effects. Vomiting was reported in five patients(13.1{\%}); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.",
keywords = "epileptic encephalopathies-childhood, refractory seizures, rufinamide",
author = "Salvatore Mangano and D'Aniello and Balestri and Parisi and Zamponi and Spalice and Fels and Veggiotti and Pascotto and Franzoni and Curatolo and Grosso and Coppola and Alberto Verrotti and Habetswallner",
year = "2011",
language = "English",
volume = "18",
pages = "246--251",
journal = "EUROPEAN JOURNAL OF NEUROLOGY",
issn = "1351-5101",

}

TY - JOUR

T1 - Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.

AU - Mangano, Salvatore

AU - D'Aniello, null

AU - Balestri, null

AU - Parisi, null

AU - Zamponi, null

AU - Spalice, null

AU - Fels, null

AU - Veggiotti, null

AU - Pascotto, null

AU - Franzoni, null

AU - Curatolo, null

AU - Grosso, null

AU - Coppola, null

AU - Verrotti, Alberto

AU - Habetswallner, null

PY - 2011

Y1 - 2011

N2 - Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ‡50% seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6%).Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5%) and increased in five patients (13.1%). Elevenpatients (28.9%) reported adverse side effects. Vomiting was reported in five patients(13.1%); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.

AB - Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ‡50% seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6%).Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5%) and increased in five patients (13.1%). Elevenpatients (28.9%) reported adverse side effects. Vomiting was reported in five patients(13.1%); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.

KW - epileptic encephalopathies-childhood

KW - refractory seizures

KW - rufinamide

UR - http://hdl.handle.net/10447/50698

M3 - Article

VL - 18

SP - 246

EP - 251

JO - EUROPEAN JOURNAL OF NEUROLOGY

JF - EUROPEAN JOURNAL OF NEUROLOGY

SN - 1351-5101

ER -